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sleep questionnaire or on the derived MOS sleep scales. Signiﬁ-
cant improvement in the abatacept group compared to control
on sleep adequacy, sleep disturbance, somnolence and both sleep
problem indices I and II were found. For both studies,
sleep quantity was not signiﬁcantly difference between treatment
groups, but optimal sleep signiﬁcantly improved in the abatacept
vs control group: ATTAIN (18% vs -12%, p < 0.0001) and AIM
(16% vs 5%, p = 0.0214). CONCLUSION: Treatment with
abatacept improves several different aspects of sleep in RA
patients. In particular, sleep disturbance and sleep problems
given by index II are reduced, and optimal sleep is improved.
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OBJECTIVE: To examine the validity, reliability, and sensitivity
to change of a simple measure of activity participation for rheu-
matoid arthritis (RA) clinical trials. Joint damage from RA sig-
niﬁcantly limit patients’ participation of daily work and
non-work activities, however, few instruments were available to
measure treatment effect on this aspect. METHODS: We mea-
sured activity participation in two randomized clinical trials of
abatacept in active RA patients. Activity participation was
assessed by two items: 1) the number of days in the past month
a patient was unable to perform usual activities (paid or unpaid
work, or any other daily activities), and 2) how often a patient
was able to perform activities completely (scored 1–6, ranging
from none to all of the time). For construct validity, corre-
lations between the two activity items with clinical response
and patient-reported outcomes were examined. Intraclass corre-
lation coefﬁcient (ICC) was used to assess test-retest reliability,
and standardized effect sizes (SES) were calculated to evaluate
sensitivity to change. RESULTS: In both studies at baseline,
patients were limited for 15 days per month in usual activities
and the score on activity completion was 3.7. After treatment,
patients with EULAR clinical responses of good, moderate,
none, gained back 11, 9, and 4 days of activity respectively, and
patients who achieved minimal disease activity state gained
12 days vs. those who did not (7 days). Similar pattern was
observed for the activity completion score. Moderate to strong
correlations (0.5–0.6) between the two activity items with
physical function, patient global, pain, and fatigue were found.
The ICC for reliability was 0.6, and the SES was 0.5, indicating
good response to change. CONCLUSION: The simple activity
participation measure reﬂects true changes in patient clinical
status and quality of life. It is valid, reliable, and sensitive to
change, which suggests it is a suitable outcomes measure for
clinical trials.
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OBJECTIVE: To estimate work productivity for patients treated
with tramadol extended–release (ER) or placebo. METHODS:
Intent-to-treat patients (18–65 years old) with chronic osteoar-
thritis pain from a 12-week, randomized, double-blind, placebo-
controlled, ﬁxed-dose study and treated with tramadol ER
(100–400 mg) or placebo were compared. Work productivity
was not assessed within the study, it was estimated using an
imputation methodology. This imputation method cross-walks
other health measures into Work Limitations Questionnaire
(WLQ) scores. The WLQ is a validated questionnaire assessing
health-related decrements in job performance and work produc-
tivity (“presenteeism”). According to this method, mean change
in the Western Ontario and McMaster Universities (WOMAC)
Osteoarthritis total index scores were multiplied by the regres-
sion coefﬁcients established for the WLQ and WOMAC. Produc-
tivity gains were translated to annual US dollars inﬂated to 2007.
RESULTS: Baseline characteristics of tramadol ER and placebo
groups were comparable. After 12 weeks of treatment, the tra-
madol ER treated patients signiﬁcantly improved than placebo
(WOMAC score of 23 vs. 16 points, p = 0.002). This 23 points
improvement in WOMAC when imputed to WLQ translated
into improvement of WLQ time management (8.15%), physical
demands (11.78%), mental-interpersonal (5.99%), overall
output demands (6.95%) and improvement in work productivity
(1.96%). The improvement observed in the tramadol ER patients
when aggregated to annual dollars per employee in 2007 ranged
from [$1201–$7218], was numerically higher than placebo
treated patients [$882–$5098]. Sensitivity analyses using other
health-measures resulted in similar ﬁndings. CONCLUSION:
Treatment with tramadol ER resulted in signiﬁcant improvement
in pain and physical function, when imputed to WLQ corre-
sponded to productivity improvement.
PMS39
LOSS OF EMPLOYABLE LIFE-YEARS IN PATIENTSWITH
RHEUMATOID ARTHRITIS:A PRELIMINARY ANALYSIS USING
MARKOV MODEL
Han C1,Tang B2, Parasuraman S3
1Johnson & Johnson Pharmaceutical Services, LLC, Malvern, PA, USA,
2Centocor, Inc, Horsham, PA, USA, 3Johnson & Johnson
Pharmaceutical Services, L.L.C, Malvern, PA, USA
OBJECTIVE: To estimate loss of employable life-years over time
in patients with rheumatoid arthritis (RA). METHODS: We used
a Markov model to estimate employable life-years using data
from ASPIRE, a randomized clinical trial comparing the efﬁcacy
and safety of inﬂiximab + methotrexate (MTX) (IFX group)
and placebo + MTX (MTX group) among early RA patients.
Employability state was deﬁned as ‘unemployable’ if patients
were unemployed and felt unable to work even if a job was
available or ‘employable’ if patients were employed or felt well
enough to work if a job were available. The one-year transition
probability of employability was estimated using a logistic
regression model, and loss of employable life-years was estimated
using a two-state Markov model. RESULTS: For a patient at age
45 years, 31.4 % of female and 29.7% of male were unemploy-
able using the regression model. For patients starting at age 45
and employable, the probability of remaining employable after
one-year of treatment was 0.928 in males and 0.905 in females in
the IFX group, and 0.899 in males and 0.867 in females in the
MTX groups, respectively. For patients unemployable, the prob-
ability to be employable after one-year treatment was 0.481 in
males and 0.405 in females in the IFX groups, and 0.390 in males
and 0.319 in females in the MTX groups, respectively. In the
Markov model, after 10 years at age 55, 18.5% of females and
14.1% of males in the IFX groups, and 30.7% of females and
24.2% of males in the MTX groups will be unemployable. On
average, 0.99 employable life-years will be saved per patient over
10 years in IFX-treated patients compared to MTX-treated
patients. CONCLUSION: This analysis presents a new method
to estimate employable life-years using a Markov model, and
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demonstrated that IFX-treated patients could gain economic
beneﬁt by retaining employability over time.
MUSCULAR-SKELETAL DISORDERS—Health Care Use
& Policy Studies
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OBJECTIVE: To assess the preference of Brazilians for drugs
with different dosing and methods of application to treat chronic
diseases, such as osteoporosis. The assessed product types were:
once-monthly oral, injection once every three months, and
once-yearly injection. METHODS: Quantitative study per-
formed through personal and individual interviews. A represen-
tative sample of the study population (N = 392 subjects) was
used. Subjects over 45 years old were interviewed. A 14-item
structured questionnaire was used. A card with the drug charac-
teristics (dosing, cares of administration, side effects and annual
treatment cost) was shown to the interviewed subjects.
RESULTS: Fourty-four percent of the interviewed subjects were
male and 56% were female. Sixty percent of the interviewed
subjects were between 45 and 59 years old, and the other 40%
were 60 years old or more. Fourteen percent of the interviewed
subjects belonged to the Brazilian socioeconomic classiﬁcation
“A”, followed by 39% in the classiﬁcation “B”, and 47% in the
classiﬁcation “C”. Twenty-eight percent had higher education,
followed by 29% with secondary education, and 42% with
primary education. Ninety-three percent of the interviewed sub-
jects do not usually take injection drugs. For treatment of chronic
diseases, 72% of the patients prefer oral drugs, 16% prefer
injection drugs diluted in serum, 9% prefer injection drugs, and
3% did not inform their preference. These percentages remained
the same when dosing, side effects and prices were disclosed.
83% of the patients who chose oral drug did it so by convenience
of the dosing, 21% of them also think that oral drugs have fewer
side effects than injection drugs. Generically comparing (not
considering the card with product proﬁles) oral and injection
drugs, 78% of the population prefer oral treatments. CONCLU-
SION: If patients are given the chance to choose between oral or
injection drugs to treat chronic diseases, 78% prefer oral drugs
instead of injection ones.
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OBJECTIVE: To determine the differences in the patterns and
costs of health care utilization between recipients with Rheuma-
toid Arthritis (RA) with versus without comorbid depression
enrolled in a state Medicaid program. METHODS: A retrospec-
tive cross-sectional analysis of a de-identiﬁed state Medicaid
fee-for-service administrative claims dataset was conducted. The
target population included recipients between 15–64 years old
who were continuously eligible for beneﬁts between January 1,
2002 and December 31, 2003. Recipients with at least one
medical services claim with a primary diagnosis of RA in 2002
were selected. The sample was then dichotomized between those
with versus without a medical claim with a primary diagnosis of
depression during 2002. Data from calendar year 2003 was used
to compare the patterns of RA-related ofﬁce services and pre-
scription medication utilization and related costs between the
two groups. RESULTS: There were 763 recipients identiﬁed with
RA, of whom 244 (31.9%) had comorbid depression. A signiﬁ-
cantly (p < 0.05) higher proportion of recipients 21–44 years of
age (41.9%), females (34.4%), and whites (32.0%) with RA had
comorbid depression. Negative binomial regression controlling
for demographic variables and comorbidities showed the fre-
quency of ofﬁce visit utilization was signiﬁcantly (p < 0.05) lower
for recipients with comorbid depression than those without
depression. A signiﬁcantly (p < 0.05) higher proportion of recipi-
ents without depression than with depression had a claim for a
DMARD (49.4% versus 31.9%) and a biologic agent (17.0%
versus 10.0%). The average annual amount paid by Medicaid
per recipient for the use of ofﬁce services and prescription medi-
cations was signiﬁcantly (p < 0.05) higher for recipients without
depression ($2914) than with depression ($2049). CONCLU-
SION: Roughly one-third of the recipients with RA had comor-
bid depression. The use of primary care ofﬁce services and
prescription medications that can slow the progression of RA
was lower among recipients with depression than without
depression.
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OBJECTIVE: Acetaminophen (paracetamol) and non-steroidal
anti-inﬂammatory drugs (NSAIDs) are common prescription
and nonprescription medications for osteoarthritis (OA). British
Columbia (BC) PharmaNet data contains one record for every
prescription. The National Population Heath Survey (NPHS)
includes prescription and nonprescription medications, but the
BC sample is small. Our objective is to explore the utility of large
prescription-only databases in studying drugs with nonprescrip-
tion forms. We compare acetaminophen and NSAIDs according
to OA and disease duration (OAD), and compare results from
NPHS versus PharmaNet. METHODS: Medications in the 2002/
2003 NPHS (Canada = 11717, BC = 1101) refer to the two days
before the interview. Statistics Canada classiﬁed responses by
ATC. OA was self-reported. In Medical Services Plan (MSP) data,
ICD-9 codes determined OA. PharmaNet (n = 100,000) was
linked to MSP, and weighted according to the 2003 BC popula-
tion. Medication use from PharmaNet/NPHS was compared
by age, sex and OAD. RESULTS: PharmaNet: acetaminophen
ranged from 0.04% in ages 0–49 without OA to 6.7% in 50–59
with OAD > 6 years. OAD increased use. NSAID ranged from
0.43% in 0–49 without OA to 10.7% in 70+ with OAD > 6
years. OAD and older age increased use. NPHS: acetaminophen
ranged from 5.1% to 15.8%. OA disease increased use. NSAID
ranged from 8.9% in 0–49 without OA to 32.6% in 70+ with
OAD > 6 years. OAD and older age increased use. The ratio of
acetaminophen in NPHS/PharmaNet ranged from 1.25 (50–59
with OAD > 6 years) to 175.7 (0–49 without OA). The ratio of
NSAID ranged from 3.04 to 20.6. CONCLUSION: In
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